Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00838162
Other study ID # CR015952
Secondary ID TMC310911-TIDP21
Status Completed
Phase Phase 2
First received February 5, 2009
Last updated June 3, 2013
Start date June 2009
Est. completion date February 2011

Study information

Verified date June 2013
Source Tibotec Pharmaceuticals, Ireland
Contact n/a
Is FDA regulated No
Health authority Ireland: Irish Agriculture and Food Development AuthorityGermany: Ethics Commission
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the antiviral activity as measured by the change in viral load from baseline in the 14 days following initiation of treatment with 4 different dose regimens of TMC310911 co-administered with ritonavir.


Description:

This is an open-label (all people know the identity of the intervention) and randomized (study medication assigned by chance) study in treatment-naive human immunodeficiency virus type 1 (HIV-1)-infected participants (participants who had not been treated with a therapeutic HIV vaccine within 1 year prior to enrollment and who had never been treated with an antiretroviral [ARV] medication indicated for the treatment of HIV-infection or ARVs for treatment of hepatitis B infection with anti-HIV activity prior to screening). In this study approximately 32 participants will be enrolled and randomly assigned to receive 4 different dose regimens co-administered with ritonavir (8 participants in each dosing regimen). The trial will consist of a screening period (maximum 6 weeks), a treatment period with TMC310911 (2 weeks), and a follow-up period (4 weeks). Safety evaluation will include assessment of adverse events, clinical laboratory tests, vital sign measurements, physical examinations and electrocardiograms.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date February 2011
Est. primary completion date August 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Documented human immunodeficiency virus type 1 (HIV-1) infection for at least 6 months prior to the screening date

- Participant who has not been treated with a therapeutic HIV vaccine within 1 year prior to enrolment and has never been treated with an antiretroviral (ARV) medication indicated for the treatment of HIV infection or ARVs for treatment of hepatitis B-infection with anti-HIV activity

- Participant agrees not to start antiretroviral therapy (ART) before the baseline visit

- Able to comply with the protocol requirements and have good accessible veins

- HIV-1 plasma viral load at screening visit of above 5,000 HIV-1 Ribonucleic acid copies/mL

- CD4+ cell count above 200 cells/mm3 at screening

Exclusion Criteria:

- HIV-2 infected participants and/or participants with any active or chronic hepato-renal disease

- Life expectancy of less than 6 months

- Documented acute (primary) HIV-1 infection

- Pre-existing protease inhibitor (PI) medication resistance

- Any currently active Acquired Immunodeficiency Syndrome (AIDS) - defining illness

- Any active clinically significant disease or findings during screening or medical history or physical examination that in the investigator's opinion, would compromise the outcome of the study

- Any confirmed grade 3 or 4 toxicity according to the Division of AIDS (DAIDS) grading scale at screening

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
TMC310911 75 mg twice daily
TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
TMC310911 150 mg twice daily
TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
TMC310911 300 mg twice daily
TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
TMC310911 300 mg once daily
TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
Ritonavir 100 mg twice daily
Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
Ritonavir 100 mg once daily
Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tibotec Pharmaceuticals, Ireland

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Changes From Baseline in Plasma log10 Human Immunodeficiency Virus Type 1 Ribonucleic Acid (HIV-1 RNA) The antiviral activity of TMC310911 is measured by the change in viral load from baseline in the 14 days of treatment following initiation of treatment with 4 different dosing regimens of TMC310911 coadministered with ritonavir. Baseline (Day 1), Day 8, Day 15 No
Secondary Number of Participants With Virologic Response at Any Timepoint During the 14-day Treatment Period Virologic response is a viral load test result below a chosen threshold value (less than 50 copies/mL, less than 400 copies/mL, or at least 1 log drop in viral load) at any timepoint during a 14-day treatment of 4 different dose regimens of TMC310911 coadministered with 100 mg ritonavir. 14 days No
Secondary Mean Changes From Baseline in CD4+ Cell Count Baseline (Day 1), Day 8, Day 15 No
Secondary Maximum Plasma Concentration (Cmax) of TMC310911 Day 1 and Day 14 No
Secondary Time to Reach the Maximum Plasma Concentration (Tmax) of TMC310911 Day 1 and Day 14 No
Secondary Area Under the Plasma Concentration-time Curve (AUC12) From the Time of Administration of TMC310911 up to 12 Hours After Dosing Day 1 and Day 14 No
Secondary Predose Plasma Concentration (C0h) of TMC310911 Day 2, Day 3, Day 4, Day 6, Day 8, Day 10, Day 12 and Day 14 No
Secondary Average Steady-state Plasma Concentration (Css,av) of TMC310911 Day 14 No
Secondary Fluctuation Index of TMC310911 Fluctuation index, ie, percentage fluctuation: variation between maximum (Cmax) and minimum (Cmin) plasma concentration at steady-state, calculated as: 100 x ([Cmax-Cmin]/Css,av). Css,av is an average steady-state plasma concentration. Day 14 No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05261191 - A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy Phase 1
Completed NCT00540449 - TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine. Phase 3
Completed NCT02269917 - Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants Phase 3
Completed NCT00110305 - A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines Phase 2
Completed NCT00128830 - A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study Phase 2
Active, not recruiting NCT02494986 - A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies Phase 2
Active, not recruiting NCT04644029 - Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) Phase 3
Withdrawn NCT00719823 - Maraviroc Compassionate Use Phase 3
Completed NCT02547870 - A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long‐Acting Nanosuspension of Rilpivirine on Pharmacokinetics Phase 1
Withdrawn NCT05700734 - MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002) Phase 1